I would like to update you on Airware’s development updates in our march to non-invasive glucose monitoring.

We have a set of issued patents that protect the breakthrough technology that Airware is bringing to market.

We also note our ability to provide the electronic component advancements necessary to shrink our sensor hardware to the smart watch market.

Our breakthrough revolves around the minimization of scattering noise involved with optical sensing in liquids.  Our method of scanning through the hand web with a light beam, with alternate and sequential narrow wavelength light pulses traveling exact same path through the hand web provides the required high signal to noise sensitivity for useful accuracies. With our technique we are “freezing time” within our skin sample so that cancellation effects can be brought to bear on scattering noise. Along with constant references, very narrow band lasers, allowances for interfering compounds in skin, we are able to provide accurate measurements of glucose without finger sticking.

As our primary market is in replacing finger stick strips and invasive CGM patches.  All of the hardware, disposables, and software involved with managing blood sugar measurement represent a $24B market.

Our portfolio of issued patents is quite strong, and an international PCT was returned with all 21 of our claims granted and literally no prior art clearing the path for successfully worldwide patents.

# 1 – 9,606,053 Core technology – solves the scattering dilemma in a liquid

# 2 – 9,678,000 Applies tech to glucose sensing

# 3 – 9,726,601 Est. extension of technique we call “tailored interference control”

# 4 – 9,823,185 Reflective sensing for future use

# 5 ‐10,041,881 Refines multivariate approach incorporating signal, reference, and interfering compound lasers to address sensing in complex liquids

Ours expanding support relationships now include Syracuse University, UC Santa Barbara, and the William Sansum Diabetes Center in Santa Barbara.

Our hardware supports multiple laser substrates which are being delivered along with the integrated signal generators, analog to digital converters, and integrated fast microprocessors.

I have attached a non-confidential description of the company and project.  We are interested in discussing working with your organization in advancing this technology in the marketplace.

At this point, the company has achieved the following milestones in product development:

• Established concept based on recent investigations at Baylor University under contract to Airware, Inc.
• Established existence of glucose absorption bands in the near IR in the critical “optical tissue window”
• Established real detection of increasing glucose levels by increasing attenuation of signal in both water and in rabbit blood
• Filed three recent patents to protect DILAST™ technology and its investigative use for measuring concentration of compounds in human skin
• Built a working optical bench and analysis software test platform
• Produced data showing efficacy of the investigative technique for assessing glucose in phantom tissue samples with non-specific lasers available off-the-shelf
• Developed relationships with key vendors to support next step custom hardware requirements.

 

The OptoScannar™ device is a non-invasive, optical monitor that senses THC concentration in blood, eliminating the need for invasive blood extraction. Through a novel technique for illumination and direct absorption in the “optical tissue window”, we minimize the scattering effects of light in tissue achieving high “signal to noise” for detection of specific absorption levels for fast, accurate measurements.

OptoScannar’s target markets are:

· Law enforcement – Requires a portable, field sobriety detector for monitoring THC levels in blood.

· Doctors and hospitals – Administering and monitoring patients using cannabinoid therapy.

· Home medical users – Monitoring various cannabinoid products for best effectiveness.

· Recreational users – Monitoring residual THC levels for legal compliance at work and driving.

The THC sensing technique is non-invasive, accurate, and fast. Users of cannabinoids will now be able to measure total dose levels and monitor their trailing residual levels for managing their dosing regimens. Law enforcement will now have a portable evaluation method to assist in fair and legal field sobriety testing. Our sensing technique can also be tuned to sense other compounds in skin such as CBD and THCV.

Airware’s Direct Infrared Laser Absorptive Scattering Technique (DILAST™) brings the “time” element into play by employing fast alternate and sequential pulses from a signal and a reference narrow-band light source. The signal radiation is preferentially absorbed by the targeted molecules and the reference radiation, which is close in wavelength to that of the signal and has minimal absorption by the targeted molecules in the medium under test. The detector outputs of the fast pulse pairs, which see essentially the same fixed environment, are ratioed and appropriately averaged to generate the concentration of the targeted molecules.

In this optical measurement arrangement, both the signal and reference beams essentially experience the same scattering events differing only in the absorption of the targeted molecule. The effect of deleterious scattering on the measurement is significantly suppressed.

Currently, OptoScannar™ has filed four patents. The company is pre-money and sixteen months from distributing initial devices. Our plan is to work with a contract manufacturer in the U.S. to build, test, calibrate, and package the hardware.

We are aware of potential competition from breathalyzer devices and saliva tests in development. For the time being, a blood test requiring about 7 ml is the most precise measurement of active THC. The OptoScannar™ will potentially become the fast, accurate, non-invasive standard for THC home and law enforcement field testing.

As part of the AirWare / GlucoWare, we are exploring opportunities to test for THC levels in the bloodstream. This is key to understanding levels of THC for safe driving, a key area of interest for all states, not just the ones with legal / medical programs.